Callan Capital LLC Purchases 12,010 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Callan Capital LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 89.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 25,461 shares of the company’s stock after acquiring an additional 12,010 shares during the period. Callan Capital LLC’s holdings in Takeda Pharmaceutical were worth $354,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TAK. Rise Advisors LLC bought a new stake in Takeda Pharmaceutical in the 1st quarter worth $26,000. GAMMA Investing LLC bought a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at about $28,000. Principal Securities Inc. bought a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at about $28,000. First United Bank & Trust bought a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at about $29,000. Finally, Lindbrook Capital LLC boosted its stake in shares of Takeda Pharmaceutical by 40.6% during the 4th quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock valued at $58,000 after purchasing an additional 1,174 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.8 %

Shares of TAK traded up $0.10 during trading hours on Wednesday, reaching $13.25. 779,768 shares of the company traded hands, compared to its average volume of 1,676,701. The company’s fifty day moving average price is $13.15 and its two-hundred day moving average price is $13.85. The company has a market capitalization of $41.93 billion, a price-to-earnings ratio of 24.05, a price-to-earnings-growth ratio of 0.37 and a beta of 0.54. The company has a quick ratio of 0.58, a current ratio of 1.11 and a debt-to-equity ratio of 0.62. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $16.39.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.